Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760249 | 1.00 | CYP1A2 (0.59) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL2760246 | 1.00 | CYP1A2 (0.59) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL12568585 | 0.98 | CYP1A2 (0.62) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL9927921 | 0.98 | CYP1A2 (0.62) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL6079950 | 0.98 | CYP1A2 (0.62) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL4718925 | 0.98 | CYP1A2 (0.62) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL9245345 | 0.98 | CYP1A2 (0.62) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL12568590 | 0.95 | CYP1A2 (0.64) | CYP1A2HTR6CHRM5ADRA2C | |
| SCHEMBL9927920 | 0.95 | CYP1A2 (0.53) | CYP1A2HTR6 | |
| SCHEMBL9733679 | 0.95 | CYP1A2 (0.64) | CYP1A2HTR6CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-7960402-B2 | Trans-5'-(2-fluoroethoxy)-3'-oxo-N-methyl-N-(2-piperidin-1-ylethyl)-spiro[cyclohexane-1,1'-(3'H)-isobenzofuran]-4-carboxamide hydrochloride; histamine H3 receptor antagonist or inverse agonist; metabolic disorders; circulatory diseases; nervous system diseases; psychological disorders; sleep disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100240611-A1 | METHODS FOR PREPARING DPP-IV INHIBITOR COMPOUNDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-09-23 | — | — | US | disclosed |
| US-20100240611-A1 | METHODS FOR PREPARING DPP-IV INHIBITOR COMPOUNDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-09-23 | — | — | US | disclosed |
| US-20100240611-A1 | METHODS FOR PREPARING DPP-IV INHIBITOR COMPOUNDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-09-23 | — | — | US | disclosed |
| WO-2010107809-A2 | METHODS FOR PREPARING DPP-IV INHIBITOR COMPOUNDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-09-23 | — | — | WO | disclosed |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | MSD K.K. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-7378430-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378430-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-7173042-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173042-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240611-A1 | METHODS FOR PREPARING DPP-IV INHIBITOR COMPOUNDS | DPP4, DPP3, DPP7 | CYP1A2 3238/4885HTR6 1390/4885CHRM5 4771/4885 |
| US-20070155788-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP1A2 398/4885HTR6 1961/4885CHRM5 504/4885 |
| US-20070117843-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP1A2 398/4885HTR6 1961/4885CHRM5 504/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | CYP1A2 3729/4885HTR6 3811/4885CHRM5 1465/4885 |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | HRH3, HRH4, HRH2 | CYP1A2 3205/4885HTR6 264/4885CHRM5 36/4885 |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | PDE5A, PDE3A, PDE2A | CYP1A2 398/4885HTR6 1961/4885CHRM5 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.